We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck has inked a deal worth more than $525 million with preclinical biotech Synthekine to develop and commercialize novel cytokine therapeutics that focus on autoimmune diseases. Read More
Johnson & Johnson (J&J) has settled “substantially all” of the thousands of Risperdal (risperidone)-related lawsuits filed in the U.S. — which had alleged that the company’s anti-psychotic drug caused males to grow breast tissue. Read More
In 2018, Aegerion entered into a $40 million settlement with the Justice Department over charges that it marketed Juxtapid for uses the FDA never approved. Read More
Takeda Pharmaceuticals is expanding its off-the-shelf CAR-T cell program yet again, with the acquisition of GammaDelta Therapeutics, a company researching the unique abilities of gamma delta T-lymphocytes to attack blood cancers and solid tumors. Read More
Sales of Aduhelm and any other antiamyloid antibodies approved in the future will hinge on the National Coverage Determination for the new class of drugs. Read More
A federal judge has ruled that Eli Lilly must pay 2 percent of its billions in insulin sales to business development service firm Research Corp. Technologies (RTC) because the drugmaker had signed a royalty agreement in 1992 allowing Lilly to use a specific strain of yeast to make the medicines. Read More
The agreement will make Alunbrig available to Point32Health’s more than 2 million members “with Takeda standing behind the medicine with a unique outcomes-based structure,” the companies said. Read More
Biogen has so far netted just $300,000 from the sale of Aduhelm, its controversial antiamyloid antibody, a fraction of what the company anticipated for its recently approved Alzheimer’s treatment. Read More
Since the pandemic began, the Gates Foundation has previously spent $1.9 billion to support research and development and manufacturing efforts for COVID-19 vaccines, drugs and tests. Read More
Takeda Pharmaceutical has signed a risk-sharing agreement with Point32Health, the second-largest health plan in New England, that has Takeda returning a portion of the cost of its lung cancer drug Alunbrig in circumstances when it doesn’t work. Read More